IgA Nephropathy, Lymphocyte Homing and IgA Class Switch (NIDOCIGA)
IgA nephropathy (IgAN) is the most common primary glomerulonephritis in the world and it represents an important cause of end-stage kidney failure. This disease was described as a distinct entity in 1968 by J Berger and N Hinglais. The aetiology and the pathogenesis remain still obscure. Clinical observations and immunisation studies indicate that IgAN represents a dysregulation of the immune system, rather than an intrinsic renal abnormality. Twenty years ago, some authors proposed the mucosa-bone marrow axis to explain the pathogenesis of the disease. Mucosal IgA plasmocytes are displaced and take up residence in systemic sites. The unusual characteristics featured by the IgA produced by these cells (charge, size, glycosylation) drive their accumulation, deposition and mesangial activation characteristic of IgAN.
Evidence is emerging that altered lymphocyte homing may ultimately explain this aberrant localization.
|Study Design:||Intervention Model: Single Group Assignment
Masking: Open Label
|Official Title:||IgA Nephropathy, Lymphocyte Homing and IgA Class Switch|
- The Primary Outcome Measure of this study is the level of expression of the molecules of intestinal localization. [ Time Frame: 30 minutes ] [ Designated as safety issue: No ]
- The secondary outcome measure is the level of expression of the homing molecules in lymphocytes B IgA memory [ Time Frame: 30 minutes ] [ Designated as safety issue: No ]
|Study Start Date:||February 2013|
|Study Completion Date:||June 2016|
|Primary Completion Date:||February 2014 (Final data collection date for primary outcome measure)|
Please refer to this study by its ClinicalTrials.gov identifier: NCT01775527
|University Hospital, Limoges|
|Limoges, France, 87 042|
|Principal Investigator:||Ahmed Boumediene, doctor||University Hospital, Limoges|